Marlborough, MA, United States
Marlborough, MA, United States

Time filter

Source Type

Patent
Sunovion Pharmaceuticals | Date: 2017-03-22

Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.


Patent
Sunovion Pharmaceuticals | Date: 2017-03-22

Dosage forms and treatment regimens employing dasotraline for treating Attention Deficit Hyperactivity Disorder (ADHD) are disclosed. The compositions described herein exhibit no abuse potential.


Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.


Patent
Sunovion Pharmaceuticals | Date: 2015-10-28

Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms thereof; a crystalline hydrochloride salt of transnorsertraline or a hydrate thereof; as well as the use of the pharmaceutical composition and the salt for the treatment of CNS diseases, including depression.


Patent
Sunovion Pharmaceuticals | Date: 2016-05-25

Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising ()-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinsons disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.


Patent
Sunovion Pharmaceuticals | Date: 2016-01-20

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.


Patent
Sunovion Pharmaceuticals and PGi | Date: 2016-02-11

Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R^(a), R^(1), R^(2), R^(3), R^(4), R^(6), w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.


Patent
Sunovion Pharmaceuticals | Date: 2016-01-22

Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.


Patent
Sunovion Pharmaceuticals | Date: 2016-02-02

Compounds that modulate GluR5 activity and methods of using the same are disclosed.


Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A^(1), A^(2), R^(6), w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Loading Sunovion Pharmaceuticals collaborators
Loading Sunovion Pharmaceuticals collaborators